Saratov JOURNAL of Medical and Scientific Research

Morphofunctional features of macular area in patients with diabetic macular edema during the treatment with a dexamethasone implant in the vitrectomized eyes

Year: 2021, volume 17 Issue: №3 Pages: 434-438
Heading: Ophthalmology Article type: Original article
Authors: Arzhukhanov D.D., Petrachkov D.V.

Objective: to assess the dynamics of changes in the morphofunctional parameters of the macular zone in patients with diabetic macular edema (DME) with intravitreal dexamethasone implant (IVD) in vitrectomized eyes and eyes with a native vitreous (NV). Material and methods. The study involved 60 patients (60 eyes) divided into two groups with a diagnosis of diabetic retinopathy, DME. Group 1 — patients with NV, group 2 — with vitrectomized eyes. The best corrected visual acuity (BCVA), optical coherence tomography (ОСТ), ОСТ angiography and microperimetry were evaluated before, 1, 3 and 6 months after IVD. Results. In both groups, an increase in the average BCVA after IVD up to 3 months of monitoring (p<0.01); exponential decrease in central retinal thickness from 1 to 3 months (p<0,01), and an increase by 6 months (p<0.05); an increase in total vascular density during 6 months of monitoring (p<0.05); the average photosensitivity (PS) increased in group 1 — up to 3 months, and returned to the initial parameters by 6 months (p<0.05); in group 2 — up to 6 months (p<0.05); Parameter К (the number of points with PS below 24 dB) decreased in group 1 to 3 months (p<0.05) and returned to baseline by 6 months; in group 2 — during the entire observation period (p<0.01). Conclusion. IVD in DME may significantly improve the morphofunctional parameters of the macular zone in the eyes with both NV and vitrectomized eyes. The maximum effect of the drug was observed on the 3rd month of monitoring.

1. Klein R, Klein BE, Moss SE, et al. Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91 (12): 1464-74.
2. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103(12): 1796-806.
3. Korobelnik JF, Do DV, Schmidt-Erfurth U. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121 (11): 2247-54. DOI: https://doi.Org/10.1016/j.ophtha. 2014.05.006.
4. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema. The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120 (10): 2013-22. DOI: https://
5. Romano MR, Allegrini D, Guardia CD. Vitreous and intraretinal macular changes in diabetic macular edema with and without fractional components. GraefesArch Clin Exp Ophthalmol 2019; 257 (1): 1-8. DOI: 73-8.
6. Petrachkov DV, Budzinskaya MV, Arzhukhanov DD. The role of peeling of the inner bordering membrane of the retina in the treatment of diabetic macular edema. The Russian Annals of Ophthalmology/Vestnik Oftalmologii 2020; 136 (4): 359-66.
7. Malcles A, Dot С, Voirin N, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: the Reldex study. Retina 2017; 37 (4): 753-60.
8. American Society of Retina Specialists. FDA approves revised indication for Ozurdex for diabetic macular edema. URL:
9. Callanan D, Loewenstein A, Patel S, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. GraefesArch Clin Exp Ophthalmol 2017; (255): 463-73.
10. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114 (10): 1860-7.
11. Bobykin EV. Influence of the compliance level on the effectiveness of antiangiogenic therapy for neovascular age-related macular degeneration. The Russian Annals of Ophthalmology/Vestnik Oftalmologii 2014; 130 (4): 88-96.
12. Bilgic A, Sudhalkar A, Kodjikian L. Pro Re Nata dexamethasone implant for treatment-naive phakic eyes with diabetic macular edema: a prospective study. Ophthalmol Retina 2019; 3 (11): 929-37. DOI: https://doi.Org/10.1016/j.oret. 2019.05.027.
13. Vingrys AJ, King-Smith PE. A quantitative scoring technique for panel tests of color vision. Invest Ophthalmol Vis Sci 1988; 29(1): 50-63.
14. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology: vasogenic versus Inflammatory. J Diabetes Res 2016; 2016: 2156273. DOI: 10.1155/2016/2156273.
15. Calvo P, Abadia B, Ferreras A, et al. Diabetic macular edema: options for adjunct therapy. Drugs 2015; 75 (13): 1461-9.
16. Medeiros MD, Alkabes M, Navarro R, et al. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther 2014; (30): 709-16.

2021_03_434-438.pdf554.58 KB

No votes yet